Presentations & Publications Chapter Grimison P, Toner G. Management of advanced germ cell tumors: IGCCC intermediate- and poor-risk patients In: Scardino P, Marston Linehan W, Zelefsky M, Vogelzang N, Rini B, Bochner B, et al., editors. Comprehensive textbook of genitourinary oncology. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 594-602.
Conference presentations Davis I. ANZUP trials. Clinical Oncological Society of Australia 38th Annual Scientific Meeting; 15–17 Nov 2011; Perth. Davis I, Blinman P, Troon S, Claringbold P, Gurney H, Eisen T, Boland A, Thompson J, Stockler M. SORCE: a phase III, randomised, double-blind trial of sorafenib in patients with resected primary renal cell carcinoma at high or intermediate risk of relapse. Clinical Oncological Society of Australia 38th Annual Scientific Meeting; 15–17 Nov 2011; Perth. Davis I, Gebski V, Chatfield M, Grimison P, Kannourakis G, Boland A, Thompson J, Stockler M. EVERSUN: a phase 2 trial of everolimus alternating with sunitib as first-line therapy for advanced renal-cell carcinoma. Clinical Oncological Society of Australia 38th Annual Scientific Meeting; 15–17 Nov 2011; Perth. Grimison P. Current status of the ANZUP germ cell trials. Clinical Oncological Society of Australia 38th Annual Scientific Meeting; 15–17 Nov 2011; Perth. Grimison P, Stockler M, Thomson D, Chatfield M, Friedlander M, Gebski V, Boland A, Gurney H, Rosenthal M, Toner G. Accelerated BEP for advanced germ cell tumours: an Australian multicentre phase I/II trial. Medical Oncology Group of Australia Annual Scientific Meeting; 10–12 Aug 2011; Adelaide. Grimison P, Stockler M, Thomson D, Chatfield M, Friedlander M, Gebski V, Boland A, Gurney H, Rosenthal M, Toner G. Accelerated BEP for advanced germ-cell tumours: an Australian multicentre phase I–II triaL. Clinical Oncological Society of Australia 38th Annual Scientific Meeting; 15–17 Nov 2011; Perth. Grimison P, Thomson D, Stockler M, Chatfield M, Friedlander M, Gebski V, Boland A, Houghton B, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong S, Lewis C, Vasey P, Toner G, Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Accelerated BEP for advanced germ cell tumors: an Australian multicenter phase I/II trial. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago. Grimison P, Thomson D, Stockler M, Friedlander M, Gebski V, Boland A, Chatfield M, Rosenthal M, Gurney H, Toner G, Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Accelerated BEP for advanced germ cell tumours: an ongoing multi-centre phase I/II trial. Australia New Zealand Gynaecological Oncology Group Annual Scientific Meeting; 23–26 Feb 2011; Gold Coast. Hayne D, Stockler M, Ives A, Houghton B, Braganza P, Chalasani V, Patel M, ANZUP Bladder Cancer Subcommittee. Sequential BCG and mitomycin intravesical therapy versus BCG alone for high-risk non-muscle invasive bladder cancer: pilot study and proposal for a 2-stage randomized phase III trial. Urological Society of Australia and New Zealand 64th Annual Scientific Meeting; 21-23 Feb 2011; Christchurch. Houghton B, Grimison P, Toner G, Chatfield M, Thomson D, Friedlander
24
M, Gebski V, Boland A, Rosenthal M, Gurney H, Stockler M. The effect of pulmonary function testing on bleomycin dosing in germ-cell tumors. ASCO Genitourinary Cancers Symposium; 17–19 Feb 2011; Orlando. Houghton B, Hayne D, Brown C, Chalasani V, Patel M, Davis I, Stockler M. Intravesical chemotherapy plus BCG in non-muscle invasive bladder cancer. A systematic review with meta-analysis. Urological Society of Australia and New Zealand 64th Annual Scientific Meeting; 21–24 Feb 2011; Christchurch. Houghton B, Stockler M, Chatfield M, Toner G, Davis I, Grimison P. Patterns of care for stage-1 testicular cancer in Australia in 2010. European Multidisciplinary Cancer Congress (ECCO); 23–27 Sep 2011; Stockholm. Houghton B, Stockler M, Chatfield M, Toner G, Davis I, Grimison P. Patterns of care for stage-1 testicular cancer in Australia in 2010. Medical Oncology Group of Australia Annual Scientific Meeting; 10–12 Aug 2011; Adelaide. Olver I, Grimison P, Chatfield M, Stockler M, Toner G, Gebski V, Harrup R, Underhill C, Kichenadasse G, Singhal N, Boland A, McDonald A, Thomson D, Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Phase 2 trial of aprepitant on days 1–7 for patients with germ cell tumours having cisplatin on days 1–5. Multinational Association of Supportive Care in Cancer (MASCC); 23–25 Jun 2011; Athens. Smith A, King M, Butow P, Olver I. A comparison of data quality and practicality of online versus postal questionnaires in a sample of testicular cancer survivors. Clinical Oncological Society of Australia 38th Annual Scientific Meeting; 15–17 Nov 2011; Perth. Smith A, King M, Butow P, Olver I, Luckett T, Grimison P, Toner G, Stockler M, Hovey E, Stubbs J. Losing your marbles: understanding the psychosocial issues faced by testicular cancer survivors. IPOS 13th World Congress of PsychoOncology; 16–20 Oct 2011; Antalya, Turkey. Smith AK, M, Butow P, Olver I, Luckett T, Grimison P, Toner G, Stockler M, Hovey E, Stubbs J. Losing your marbles: the psychosocial impact of surviving testicular cancer. Clinical Oncological Society of Australia 38th Annual Scientific Meeting; 15–17 Nov 2011; Perth. Thomson D, Grimison P, Chatfield M, Stockler M, Toner G, Gebski V, Boland A, McDonald A, Olver I. Phase 2 trial of aprepitant on days 1 to 7 for patients with germ cell tumors having cisplatin on days 1 to 5. Medical Oncology Group of Australia Annual Scientific Meeting; 10–12 Aug 2011; Adelaide. Thomson D, Grimison P, Chatfield M, Stockler M, Toner G, Gebski V, Harrup R, Boland A, McDonald A, Olver I. Phase 2 trial of aprepitant on days 1 to 7 for patients with germ cell tumors having cisplatin on days 1 to 5. Clinical Oncological Society of Australia 38th Annual Scientific Meeting; 15–17 Nov 2011; Perth. Thomson D, Grimison P, Chatfield M, Stockler M, Toner G, Gebski V, Harrup R, Underhill C, Kichenadasse G, Singhal N, Boland A, McDonald A, Olver I, Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Phase II trial of aprepitant on days 1 to 7 for patients with germ cell tumors having cisplatin on days 1 to 5. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.
